CLINUVEL Pharmaceuticals (ASX:CUV) has presented clinical data from its DNA Repair Program at the 32nd meeting of the Photodermatology Society in New Orleans, USA, as part of the 2023 American Academy of Dermatology Meeting.

The data showed that afamelanotide was well tolerated and had the potential to reduce DNA photodamage in patients with genetic skin disease, xeroderma pigmentosum C (XPC).

The presentation was well received by the scientific community and recognised the potential of afamelanotide as a first-line therapy for XPC patients, to be confirmed by further study.

The Photodermatology Society is the world’s foremost meeting of experts in the fields of photomedicine, photodermatoses and phototherapy.